182 related articles for article (PubMed ID: 17997318)
1. Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors.
Morandi S; Morandi F; Caselli E; Shoichet BK; Prati F
Bioorg Med Chem; 2008 Feb; 16(3):1195-205. PubMed ID: 17997318
[TBL] [Abstract][Full Text] [Related]
2. Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.
Tondi D; Calò S; Shoichet BK; Costi MP
Bioorg Med Chem Lett; 2010 Jun; 20(11):3416-9. PubMed ID: 20452208
[TBL] [Abstract][Full Text] [Related]
3. Structure-based enhancement of boronic acid-based inhibitors of AmpC beta-lactamase.
Weston GS; Blázquez J; Baquero F; Shoichet BK
J Med Chem; 1998 Nov; 41(23):4577-86. PubMed ID: 9804697
[TBL] [Abstract][Full Text] [Related]
4. Exploring sequence requirements for C₃/C₄ carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: Insights into plasticity of the AmpC β-lactamase.
Drawz SM; Taracila M; Caselli E; Prati F; Bonomo RA
Protein Sci; 2011 Jun; 20(6):941-58. PubMed ID: 21404358
[TBL] [Abstract][Full Text] [Related]
5. Nanomolar inhibitors of AmpC beta-lactamase.
Morandi F; Caselli E; Morandi S; Focia PJ; Blázquez J; Shoichet BK; Prati F
J Am Chem Soc; 2003 Jan; 125(3):685-95. PubMed ID: 12526668
[TBL] [Abstract][Full Text] [Related]
6. Structure-based approach for binding site identification on AmpC beta-lactamase.
Powers RA; Shoichet BK
J Med Chem; 2002 Jul; 45(15):3222-34. PubMed ID: 12109906
[TBL] [Abstract][Full Text] [Related]
7. Structures of FOX-4 Cephamycinase in Complex with Transition-State Analog Inhibitors.
Lefurgy ST; Caselli E; Taracila MA; Malashkevich VN; Biju B; Papp-Wallace KM; Bonanno JB; Prati F; Almo SC; Bonomo RA
Biomolecules; 2020 Apr; 10(5):. PubMed ID: 32349291
[TBL] [Abstract][Full Text] [Related]
8. Structure-based design of a potent transition state analogue for TEM-1 beta-lactamase.
Strynadka NC; Martin R; Jensen SE; Gold M; Jones JB
Nat Struct Biol; 1996 Aug; 3(8):688-95. PubMed ID: 8756327
[TBL] [Abstract][Full Text] [Related]
9. Structure-based design and in-parallel synthesis of inhibitors of AmpC beta-lactamase.
Tondi D; Powers RA; Caselli E; Negri MC; Blázquez J; Costi MP; Shoichet BK
Chem Biol; 2001 Jun; 8(6):593-611. PubMed ID: 11410378
[TBL] [Abstract][Full Text] [Related]
10. Structures of ceftazidime and its transition-state analogue in complex with AmpC beta-lactamase: implications for resistance mutations and inhibitor design.
Powers RA; Caselli E; Focia PJ; Prati F; Shoichet BK
Biochemistry; 2001 Aug; 40(31):9207-14. PubMed ID: 11478888
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.
Drawz SM; Babic M; Bethel CR; Taracila M; Distler AM; Ori C; Caselli E; Prati F; Bonomo RA
Biochemistry; 2010 Jan; 49(2):329-40. PubMed ID: 19925018
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design guides the improved efficacy of deacylation transition state analogue inhibitors of TEM-1 beta-Lactamase(,).
Ness S; Martin R; Kindler AM; Paetzel M; Gold M; Jensen SE; Jones JB; Strynadka NC
Biochemistry; 2000 May; 39(18):5312-21. PubMed ID: 10820001
[TBL] [Abstract][Full Text] [Related]
13. Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative.
Tondi D; Venturelli A; Bonnet R; Pozzi C; Shoichet BK; Costi MP
J Med Chem; 2014 Jun; 57(12):5449-58. PubMed ID: 24882105
[TBL] [Abstract][Full Text] [Related]
14. Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design.
Usher KC; Blaszczak LC; Weston GS; Shoichet BK; Remington SJ
Biochemistry; 1998 Nov; 37(46):16082-92. PubMed ID: 9819201
[TBL] [Abstract][Full Text] [Related]
15. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK
Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535
[TBL] [Abstract][Full Text] [Related]
16. Serendipitous discovery of aryl boronic acids as β-lactamase inhibitors.
Yang SW; Pan J; Root Y; Scapin G; Xiao L; Su J
Bioorg Med Chem Lett; 2020 Jan; 30(2):126795. PubMed ID: 31759850
[TBL] [Abstract][Full Text] [Related]
17. Boronic acid inhibitors of the class A β-lactamase KPC-2.
Zhou J; Stapleton P; Haider S; Healy J
Bioorg Med Chem; 2018 Jul; 26(11):2921-2927. PubMed ID: 29784271
[TBL] [Abstract][Full Text] [Related]
18. Exploring the potential of boronic acids as inhibitors of OXA-24/40 β-lactamase.
Werner JP; Mitchell JM; Taracila MA; Bonomo RA; Powers RA
Protein Sci; 2017 Mar; 26(3):515-526. PubMed ID: 27997706
[TBL] [Abstract][Full Text] [Related]
19. Crystal structure of the IMP-1 metallo beta-lactamase from Pseudomonas aeruginosa and its complex with a mercaptocarboxylate inhibitor: binding determinants of a potent, broad-spectrum inhibitor.
Concha NO; Janson CA; Rowling P; Pearson S; Cheever CA; Clarke BP; Lewis C; Galleni M; Frère JM; Payne DJ; Bateson JH; Abdel-Meguid SS
Biochemistry; 2000 Apr; 39(15):4288-98. PubMed ID: 10757977
[TBL] [Abstract][Full Text] [Related]
20. Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC beta-lactamase.
Beadle BM; Trehan I; Focia PJ; Shoichet BK
Structure; 2002 Mar; 10(3):413-24. PubMed ID: 12005439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
